The Company is pleased to announce the closing, today, of the acquisitionof a proprietary platform technology for the rapid and efficient generationof monoclonal antibodies (MAbs). In its first application the Company willbe focusing on creating novel MAbs against cancer markers (the "MAbsTechnology").

The acquisition was made pursuant to an asset purchase agreement datedJanuary 10, 2008, with Indigoleaf Associates Ltd. and Dr. Amnon Gonenne.The consideration given for the MAbs Technology was 25,638,400 shares inthe common stock of the Company.

The Company is also pleased to announce that, in connection with theacquisition, Dr. Amnon Gonenne has been appointed as a director and thePresident and Chief Executive Officer of the Company. Dr. Gonenne replacesYapp Moi Lee who has resigned as a director and the President, ChiefExecutive Officer and Chief Financial Officer. Other changes to theCompany's management include the appointment of Dr. Elisha Orr as adirector and the Chief Technology Officer of the Company. Dr. Orr, theinventor of the MAbs Technology and a cancer researcher, replaces Pua SooSiang. Additionally, Martin Bajic has been appointed as the ChiefFinancial Officer of the Company.

About MabCure

MabCure is a biotechnology company whose vision is to change the perceptionof cancer as a largely incurable disease. MabCure owns proprietarytechnology for the creation of unique and highly specific MAbs againstseveral cancers which could potentially identify these diseases in theirearliest stage. These MAbs are the first candidates for the development ofnovel diagnostic tools, imaging agents and drugs to treat the correspondingcancers. MabCure's primary mission is to develop novel diagnostics for theearly detection of cancer when the disease is still localized andtreatable, and where the chances for cure are greater than 90 percent. Forfurther information visit the Company's website www.mabcure.com

This news release contains "forward-looking statements," as that term isdefined in Section 27A of the United States Securities Act of 1933, asamended, and Section 21E of the United States Securities Exchange Act of1934, as amended. Statements in this news release which are not purelyhistorical are forward-looking statements and include any statementsregarding beliefs, plans, expectations or intentions regarding the future.Such forward-looking statements include, among others, statements as to theintended uses of the proceeds received from the private placement.

Actual results could differ from those projected in any forward-lookingstatements due to numerous factors. Such factors include, among others,the change of business focus of the management of the Company and theinability of the Company to pursue its current objectives. Theseforward-looking statements are made as of the date of this news release andthe Company assumes no obligation to update the forward-looking statements,or to update the reasons why actual results could differ from thoseprojected in the forward-looking statements. Although the Company believesthat the beliefs, plans, expectations and intentions contained in this newsrelease are reasonable, there can be no assurance those beliefs, plans,expectations, or intentions will prove to be accurate. Investors shouldconsider all of the information set forth herein and should also refer tothe risk factors disclosed in the Company's periodic reports filed fromtime-to-time with the Securities and Exchange Commission and available atwww.sec.gov.

Distributed by Filing Services Canada and retransmitted by Marketwire